Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Nippon Kayaku to Deploy RA Reps for Remicade Biosimilar
June 9, 2014
- April Ethical Drug Sales Down 3.5%, Hurt by Pullback from Pre-Tax Hike Demand: Crecon Report
June 9, 2014
- Results from PI/PII Studies of BBI608, BBI503 Presented at ASCO Annual Meeting: DSP
June 9, 2014
- AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
- Malignant STS Treatment Trabectedin Achieves Primary Endpoint in Domestic PII Clinical Trial: Taiho
June 6, 2014
- Nihon Chouzai to Provide Online Daily Pharmacy Prescription Trend Info.
June 6, 2014
- Combination Therapy of Avastin, Tarceva Significantly Prolongs PFS in PII Study: Roche
June 6, 2014
- Sales of 26 Pharma Companies Up 10.3% Driven by Strong Overseas Sales
June 5, 2014
- Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
- Sysmex Inostics, Merck Serono of Germany to Codevelop CoDx for Erbitux for Treatment of Colon Cancer
June 5, 2014
- Eisai’s Halaven Extends OS in Metastatic Breast Cancer Patients
June 4, 2014
- Taiho’s TS-1 Able to Prolong Life for Metastatic, Relapsed Breast Cancer Patients
June 4, 2014
- Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
June 4, 2014
- Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
June 4, 2014
- Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
June 3, 2014
- Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
- MTPC to Merge Its Subsidiary Benesis in October
June 3, 2014
- Astellas Seeks Approval of Cell-Culture Seasonal Flu Vaccine
June 2, 2014
- FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
June 2, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
June 2, 2014
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…